AGE-SPECIFIC CLINICAL PRACTICE GUIDELINES FOR EARLY-ONSET BOWEL CANCER To be developed by Bowel Cancer Australia in collaboration with the Australian Living Evidence Collaboration (ALEC)
With
Dr Prasad Cooray, Medical Oncologist,
Yarra Oncology &
Clinical Researcher & Lecturer,
The University of Melbourne &
Spokesperson, Bowel Cancer Australia
SEGMENT
Filmed in Melbourne | April 2026
Each year almost 1,900 Australians are diagnosed with early-onset bowel cancer (under age 50), and they are currently managed according to clinical practice guidelines that are not age specific.
The National Health and Medical Research Council (NHMRC) has agreed to consider for approval the Clinical Practice Guidelines for the Early Diagnosis and Management of Early-Onset Colorectal Cancer (EOCRC), to be developed by Bowel Cancer Australia in collaboration with the Australian Living Evidence Collaboration (ALEC), and funded by Bowel Cancer Australia. ALEC is led by Cochrane Australia and based in the School of Public Health and Preventive Medicine at Monash University.
“Development of co-designed age-appropriate guidelines is essential given the rising rates of bowel cancer among Australians under 50 to ensure they reflect the unique clinical challenges younger people encounter,” Bowel Cancer Australia CEO Julien Wiggins said.
“The guidelines will use an established ‘living’ approach to generate up-to-date, evidence-based guidance to support clinical decision-making. As soon as new research becomes available, it can be incorporated into the guidelines and translated into clinical practice in near real-time.”
“Young Australians diagnosed with bowel cancer face a very different disease trajectory compared to older patients, yet they are managed under the same clinical framework,” Medical Oncologist and Bowel Cancer Australia spokesperson Dr Prasad Cooray, said to Australian Health Journal.
“That gap has real consequences, contributing to delayed diagnosis, more advanced stage at presentation, poorer survival outcomes, and long-term impacts on fertility, survivorship, and quality of life.
Young women are a particular concern because fertility and pregnancy can be impacted by treatment while postpartum changes can hide or confuse symptoms.
Source: Adapted from Bowel Cancer Australia media release (February 2026)
-
Clinical pain neuroscientist talks about how the brain processes pain information
Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.
Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.
Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.
-
Gaining a better understanding of perimenopause and menopause
Nearly half of women seeking help for menopause symptoms are already experiencing clinically significant distress by the time they ask for support, according to a recent national benchmark report released by Metluma.
The 2026 Australian Menopause Experience Report, based on insights from 1,468 women using Metluma’s UMA40 assessment tool, found 43% triggered at least one clinical red flag at baseline (referral to a doctor within 24-48 hours), with more than one in five presenting with multiple red flags linked to more complex symptom burden.
-
Forum fosters dialogue in breast cancer
In October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT and The University of Queensland Faculty of Medicine/Frazer Institute.
The key aim of the event co-organised by Associate Professor Joy Wolfram, Group Leader, Australian Institute for Bioengineering and Nanotechnology & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians.
